Bioventures 2014 L.P. Mpm Sells 21,623 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) major shareholder Bioventures 2014 L.P. Mpm sold 21,623 shares of Entrada Therapeutics stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $7.34, for a total transaction of $158,712.82. Following the sale, the insider owned 4,359,439 shares of the company’s stock, valued at approximately $31,998,282.26. The trade was a 0.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Bioventures 2014 L.P. Mpm also recently made the following trade(s):

• On Wednesday, August 26th, Bioventures 2014 L.P. Mpm sold 14,569 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.06, for a total value of $102,857.14.
• On Tuesday, August 25th, Bioventures 2014 L.P. Mpm sold 26,522 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.54, for a total value of $199,975.88.

Entrada Therapeutics Stock Performance

Shares of TRDA stock opened at $7.27 on Friday. The stock has a fifty day moving average price of $7.09 and a 200 day moving average price of $9.33. The stock has a market cap of $283.07 million, a PE ratio of -1.84 and a beta of -0.26. Entrada Therapeutics, Inc. has a 1 year low of $5.02 and a 1 year high of $16.45.

Entrada Therapeutics (NASDAQ:TRDA) last posted its earnings results on Wednesday, August 5th. The company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). The firm had revenue of $0.90 million for the quarter, compared to analysts’ expectations of $2.32 million. Entrada Therapeutics had a negative return on equity of 57.61% and a negative net margin of 3,537.73%. As a group, equities research analysts predict that Entrada Therapeutics, Inc. will post -4.03 earnings per share for the current year.

Analyst Ratings Changes

TRDA has been the topic of a number of research reports. Roth Capital reissued a “buy” rating and issued a $11.00 price objective on shares of Entrada Therapeutics in a research note on Wednesday, August 12th. Guggenheim reduced their price target on shares of Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating on the stock in a report on Monday, June 8th. HC Wainwright lowered shares of Entrada Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, May 8th. Finally, Weiss Ratings cut shares of Entrada Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, August 13th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Entrada Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $17.75.

Institutional Trading of Entrada Therapeutics

Large investors have recently made changes to their positions in the stock. Baker BROS. Advisors LP raised its stake in Entrada Therapeutics by 4.3% in the 4th quarter. Baker BROS. Advisors LP now owns 5,072,730 shares of the company’s stock valued at $52,148,000 after purchasing an additional 206,911 shares during the last quarter. 5AM Venture Management LLC acquired a new stake in shares of Entrada Therapeutics during the 2nd quarter worth about $29,854,949,000. BlackRock Inc. purchased a new stake in shares of Entrada Therapeutics during the second quarter worth about $19,013,000. Wellington Management Group LLP grew its holdings in shares of Entrada Therapeutics by 9.5% during the fourth quarter. Wellington Management Group LLP now owns 1,044,758 shares of the company’s stock worth $10,740,000 after buying an additional 90,339 shares in the last quarter. Finally, Millennium Management LLC raised its position in shares of Entrada Therapeutics by 391.2% in the third quarter. Millennium Management LLC now owns 836,609 shares of the company’s stock valued at $4,852,000 after buying an additional 666,287 shares during the last quarter. Institutional investors and hedge funds own 86.39% of the company’s stock.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.